CORPORATE PROFILE:
CV Technologies Inc., (TSX:CVQ) founded in 1992, strives to transform people’s lives to be healthier and happier by focusing on prevention and recovery through the use of evidence-based naturally-derived health products. The Company's lead product COLD-fX® strengthens the immune system and is widely used as a leading over the counter remedy (OTC) for helping to prevent and relieve cold and flu infections.

Investment Highlights:

	COLD-fX® approved by Health Canada to fight colds and flu by boosting the immune system
	COLD-fX remains the #1 selling cold and flu remedy in Canada*
	#1 pharmacy recommended natural cold and flu remedy in Canada
	Company is optimally positioned in the growing market for wellness approach to health maintenance and prevention of disease with natural based products
	Ongoing scientifically rigorous research into applying our proprietary products and technology to medical conditions/diseases such as cancer, high cholesterol, blood pressure management
	Exploring licensing our intellectual property for use in other industries e.g. functional foods/animal supplements
	Strong balance sheet/cash flow to support existing operations and domestic/international growth opportunities

*Source: ACNielsen Brand Overview, National All Channels Total Cold Remedies (including Antihistamines) and Natural Supplements for 52 weeks ending March 15, 2008

Milestones:

Clinical trials:  Two clinical trials have completed their treatment phase and are now in the analysis phase: 1) a Canadian multi-centre trial examining the impact of a two-fold higher dose of COLD-fX on upper respiratory infections in vaccinated seniors, versus the standard approved dose, and  2) a trial assessing the safety and immune enhancing effects of a three-day high dose of COLD-fX on front-line medical workers at Hackensack Medical Center in the United States. To ensure study integrity is maintained, both studies remain under blinded conditions while in the analysis phase. We anticipate the results of these studies will extend the understanding of the optimal conditions of use for COLD-fX and how it works, as well as add to the safety profile. Results of both studies are expected in the fourth quarter of fiscal 2008.

Key Facts:

	CVQ trades on the Toronto Stock Exchange
	Spin off from Faculty of Medicine, University of Alberta in 1992
	Life sciences company with product development focused on evidence-based preventative health care
	Breakthrough patented discovery/standardization technology is ChemBioPrint®, a crucial competitive advantage
	Clinical trials: science and evidence-based, double-blind, placebo-controlled, randomized
	Lead commercialized products: COLD-fX®, REMEMBER-fX® and CELL-fX®
	Health Canada product license to sell COLD-fX under a therapeutic claim to reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system
	U.S. FDA clearance to sell COLD-fX as an immune enhancing, New Dietary Ingredient (NDI)

Strategy:

	Extend leading position in Canada and dominate all key regional markets
	Enhance product/brand recognition and build on socially conscious, healthy, green image
	Grow existing business via new distribution channels, marketing and advertising, and product pipeline extensions
	Pursue licensing opportunities and international partnerships

Lead Commercial Products:

	COLD-fX® Regular & Extra Strength - For prevention and relief of colds and flu and strengthening the immune system
	REMEMBER-fX® - Helps temporarily restore mental alertness or wakefulness when experiencing fatigue or drowsiness
	CELL-fX® - Helps relieve symptoms of bone and joint pain and helps in the formation of connective tissue